“We’re at that exciting intersection of generating financial returns by improving lives.”

Ian A.W. Howes


Ian A.W. Howes oversees Accelerator’s financial, legal, and operations functions. He works closely with all Accelerator portfolio companies, overseeing capital markets activities and providing day-to-day financial and strategic direction.

With more than 20 years of experience in senior financial roles developing early-stage life sciences companies, Ian has completed numerous rounds of private and public equity and debt transactions, including two initial public offerings. He also has successfully managed multiple M&A transactions for companies where he served as CFO, including the sale of Scioderm to Amicus Therapeutics in 2015 and the sale of Serenex to Pfizer in 2008.

Before joining Accelerator in 2017, Ian served as CFO of Heart Metabolics, a venture capital-backed biopharmaceutical company developing drugs for cardiovascular diseases. He served as CFO of Scioderm, a pediatric orphan disease company, where, in 2015, he managed the sale of the company to Amicus Therapeutics (NASDAQ: FOLD). Prior to that, Ian served as CFO for Akebia Therapeutics (NASDAQ: AKBA), a biotechnology company developing pharmaceutical drugs for anemia and ophthalmology. Before Akebia, he served as CFO and Senior VP of Corporate Development of Serenex, an integrated discovery, and development-stage oncology company. He managed the sale of Akebia to Pfizer in 2008. Ian also served as CFO and VP Operations at Paradigm Genetics (Nasdaq: PDGM).

Ian began his professional career with Coopers & Lybrand in London and is a Chartered Accountant. He received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and has a B.S. in Accounting and Finance from the University of Warwick.